Germinal center kinase-like kinase (GLK/MAP4K3) expression is increased in adult-onset Still's disease and may act as an activity marker

BMC Medicine

Tse-Hua Tan³  Kuo-Lung Lai⁴  Wei-Ting Hung⁴  Yi-Ming Chen²  Joung-Liang Lan⁵  Huai-Chia Chuang¹  Der-Yuan Chen⁵ 

[1] Immunology Research Center, National Health Research Institutes, Zhunan, Taiwan;School of Medicine, Chung Shan Medical University, Taichung, Taiwan;Department of Pathology & Immunology, Baylor College of Medicine, Houston, Texas, USA;Division of Allergy, Immunology and Rheumatology, Taichung Veterans General Hospital and Faculty of Medicine, National Yang Ming University, Taiwan;Institute of Biomedical Science, National Chung Hsing University, Taichung, Taiwan

关键词: Th17-related cytokines;    pathogenesis;    mitogen-activated protein kinases (MAPKs);    GCK-like kinase (GLK, MAP4K3);    Adult-onset Still's disease;   

Others  :  1125904
DOI  :  10.1186/1741-7015-10-84

 received in 2012-03-16, accepted in 2012-08-06,  发布年份 2012

【 摘 要 】

Background

Germinal center kinase-like kinase (GLK, also termed MAP4K3), a member of the MAP4K family, may regulate gene transcription, apoptosis and immune inflammation in response to extracellular signals. The enhanced expression of GLK has been shown to correspond with disease severity in patients with systemic lupus erythematosus. We investigated the role of GLK in the pathogenesis of adult-onset Still's disease, which shares some similar clinical characteristics with systemic lupus erythematosus.

Methods

The frequencies of circulating GLK-expressing T-cells in 24 patients with active adult-onset Still's disease and 12 healthy controls were determined by flow cytometry analysis. The expression levels of GLK proteins and transcripts were evaluated in peripheral blood mononuclear cells by immunoblotting and quantitative PCR. Serum levels of T helper (Th)17-related cytokines, including IL-1β, IL-6, IL-17 and TNF-α, were measured by ELISA.

Results

Significantly higher median frequencies of circulating GLK-expressing T-cells were observed in patients with adult-onset Still's disease (31.85%) than in healthy volunteers (8.93%, P <0.001). The relative expression levels of GLK proteins and transcripts were also significantly higher in patients with adult-onset Still's disease (median, 1.74 and 2.35, respectively) compared with those in healthy controls (0.66 and 0.92, respectively, both P <0.001). The disease activity scores were positively correlated with the frequencies of circulating GLK-expressing T-cells (r = 0.599, P <0.005) and the levels of GLK proteins (r = 0.435, P <0.05) or GLK transcripts (r = 0.452, P <0.05) in patients with adult-onset Still's disease. Among the examined Th17-related cytokines, elevated levels of serum IL-6 and IL-17 were positively correlated with the frequencies of circulating GLK-expressing T-cells and the levels of GLK proteins as well as transcripts in patients with adult-onset Still's disease. GLK expression levels decreased significantly after effective therapy in these patients.

Conclusions

Elevated expression levels of GLK and their positive correlation with disease activity in patients with adult-onset Still's disease indicate that GLK may be involved in the pathogenesis and act as a novel activity biomarker of this disease.

【 授权许可】

   
2012 Chen et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Chang L, Karin M: Mammalian MAP kinase signaling cascades. Nature 2001, 410:37-40.
• [2]Raman M, Chen W, Cobb MH: Differential regulation and properties of MAPKs. Oncogene 2007, 26:3100-3112.
• [3]Sweeney SE, Firestein GS: Primer: signal transduction in rheumatic disease - a clinician's guide. Nat Clin Pract Rheumatol 2007, 3:651-660.
• [4]Wong CK, Li PW, Lam CW: Intracellular JNK, p38 MAPK and NF-kappaB regulate IL-25 induced release of cytokines and chemokines from costimulated T helper lymphocytes. Immunol Lett 2007, 112:82-91.
• [5]Wong CK, Wong PTY, Tam LS, Li EK, Chen DP, Lam CWK: Activation profile of intracellular mitogen-activated protein kinases in peripheral lymphocytes of patients with systemic lupus erythematosus. J Clin Immunol 2009, 29:738-746.
• [6]Noubade R, Krementsov DN, del Rio R, Thornton T, Nagaleekar V, Saligrama N, Spitzack A, Spach K, Sabio G, Davis RJ, Rincon M, Teuscher C: Activation of P38 MAPK in CD4 T cells controls IL-17 production and autoimmune encephalomyelitis. Blood 2011, 118:3290-3300.
• [7]Diener K, Wang XS, Chen C, Meyer CF, Keesler G, Zukowski M, Tan TH, Yao Z: Activation of the c-Jun N-terminal kinase pathway by a novel protein kinase related to human germinal center kinase. Proc Natl Acad Sci USA 1997, 94:9687-9692.
• [8]Findlay GM, Yan L, Procter J, Mieulet V, Lamb RF: A MAP4 kinase related to Ste20 is a nutrient-sensitive regulator of mTOR signaling. Biochem J 2007, 403:13-20.
• [9]Lam D, Dickens D, Reid EB, Loh SH, Moisoi N, Martins LM: MAP4K3 modulates cell death via the post-transcriptional regulation of BH3-only proteins. Proc Natl Acad Sci USA 2009, 106:11978-11983.
• [10]Lorenz HM, Grunke M, Hieronymus T, Herrmann M, Kuhnel A, Manger B, Kalden JR: In vitro apoptosis and expression of apoptosis-related molecules in lymphocytes from patients with systemic lupus erythematosus and other autoimmune disease. Arthritis Rheum 1997, 40:306-317.
• [11]Chen DY, Hsieh TY, Hsieh CW, Lin FJ, Lan JL: Increased apoptosis of peripheral blood lymphocytes and its association with interleukin-18 in patients with active untreated adult-onset Still's disease. Arthritis Rheum 2007, 57:1530-1538.
• [12]Chuang HC, Lan JL, Chen DY, Yang CY, Chen YM, Li JP, Huang CY, Liu PE, Wang X, Tan TH: GLK controls autoimmunity and NF-kB signaling by activating PKCθ in T cells. Nature Immunol 2011, 12:1113-1118.
• [13]Lock C, Hermans G, Pedotti R, Brendolan A, Schadt E, Garren H, Langer-Gould A, Strober S, Cannella B, Allard J, Klonowski P, Austin A, Lad N, Kaminski N, Galli SJ, Oksenberg JR, Raine CS, Heller R, Steinman L: Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med 2002, 8:500-508.
• [14]Bywaters EGL: Still's disease in the adults. Ann Rheum Dis 1971, 30:121-133.
• [15]Ohta A, Yamaguchi M, Kaneoka H, Nagayoshi T, Hiida M: Adult Still's disease: review of 228 cases from the literature. J Rheumatol 1987, 14:1139-1146.
• [16]Kawashima M, Yamamura M, Taniai M, Yamauchi H, Tanimoto T, Kurimoto M, Miyawaki S, Amano T, Takeuchi T, Makino H: Levels of interleukin-18 and its binding inhibitors in the blood circulation of patients with adult-onset Still's disease. Arthritis Rheum 2001, 44:550-560.
• [17]Chen DY, Lan JL, Lin FJ, Hsieh TY: Proinflammatory cytokine profiles in the sera and in the pathological tissues of patients with active untreated adult onset Still's disease. J Rheumatol 2004, 31:2189-2198.
• [18]Choi JH, Suh CH, Lee YM, Suh YJ, Lee SK, Kim SS, Nahm DH, Park HS: Serum cytokine profiles in patients with adult onset Still's disease. J Rheumatol 2003, 30:2422-2427.
• [19]Chen DY, Lan JL, Lin FJ, Hsieh TY, Wen MC: A predominance of Th1 cytokine in peripheral blood and pathological tissues of patients with active untreated adult-onset Still's disease. Ann Rheum Dis 2004, 63:1300-1306.
• [20]Chen DY, Chen YM, Lan JL, Lin CC, Chen HH, Hsieh CW: Potential role of Th17 cells in the pathogenesis of adult-onset still's disease. Rheumatology (Oxford) 2010, 49:2305-2312.
• [21]Yamaguchi M, Ohta A, Tsunematsu T, Kasukawa R, Mizushima Y, Kashiwagi S, Tanimoto K, Matsumoto Y, Ota T: Preliminary criteria for classification of adult Still's disease. J Rheumatol 1992, 19:424-430.
• [22]Pouchot J, Sampalis JS, Beaudet F, Carette S, Décary F, Salusinsky-Sternbach M, Hill RO, Gutkowski A, Harth M, Myhal D: Adult Still's disease: manifestations, disease course, and outcome in 62 patients. Medicine 1991, 70:118-136.
• [23]Chomczynski P, Sacchi N: Single-step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987, 162:156-159.
• [24]Krutzik PO, Irish JM, Nolan JP, Perez OD: Analysis of protein phosphorylation and cellular signaling events by flow cytometry: techniques and clinical applications. Clin Immunol 2004, 110:206-221.
• [25]Grammer AC, Swantek JL, McFarland RD, Miura Y, Geppert T, Lipsky PE: TNF receptor-associated factor-2 signaling mediates activation of p38 and Jun N-terminal kinase, cytokine secretion, and Ig production following ligation of CD40 on human B cells. J Immunol 1998, 161:1183-1193.
• [26]Grammer AC, Fischer R, Lee O, Zhang X, Lipsky PE: Flow cytometric assessment of the signaling status of human B lymphocytes from normal and autoimmune individuals. Arthritis Res Ther 2004, 6:28-39.
• [27]Yang J, Chu Y, Yang X, Gao D, Zhu L, Yang X, Wan L, Li M: Th17 and natural Treg cell population dynamics in systemic lupus erythematosus. Arthritis Rheum 2009, 60:1472-1483.
• [28]Garrett-Sinha LA, John S, Gaffen SL: IL-17 and the Th17 lineage in systemic lupus erythematosus. Curr Opin Rheumatol 2008, 20:519-525.
• [29]Zhou L, Ivanov II, Spolski R, Min R, Shenderov K, Egawa T, Levy DE, Leonard WJ, Littman DR: IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol 2007, 8:967-974.
• [30]Park H, Li Z, Yang XO, Chang SH, Nurieva R, Wang YH, Wang Y, Hood L, Zhu Z, Tian Q, Dong C: A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 2005, 6:1133-1141.
• [31]Jovanovic DV, Di Battista JA, Martel-Pelletier J, Jolicoeur FC, He Y, Zhang M, Mineau F, Pelletier JP : IL-17 stimulates the production of proinflammatory cytokines, IL-1β and TNF-α, by human macrophages. J Immunol 1998, 160:3513-3521.
• [32]Laan M, Cui AH, Hoshino H, Lötvall J, Sjöstrand M, Gruenert DC, Skoogh BE, Lindén A: Neutrophil recruitment by human IL-17 via CXC chemokine release in the airways. J Immunol 1999, 162:2347-2352.
• [33]Fedele G, Spensieri F, Palazzo R, Nasso M, Cheung GY, Coote JG, Ausiello CM: Bordetella pertussis commits human dendritic cells to promote a Th1/Th17 response through the activity of adenylate cyclase toxin and MAPK-pathways. PLoS One 2010, 5:e8734.
• [34]Roussel L, Houle F, Chan C, Yao Y, Bérubé J, Olivenstein R, Martin JG, Huot J, Hamid Q, Ferri L, Rousseau S: IL-17 promotes p38 MAPK-dependent endothelial activation enhancing neutrophil recruitment to sites of inflammation. J Immunol 2010, 184:4531-4537.
• [35]Commodaro AG, Bombardieri CR, Peron JPS, Saito KC, Guedes PM, Hamassaki DE, Belfort RN, Rizzo LV, Belfort R Jr, de Camargo MM: p38α MAP kinase controls IL-17 synthesis in Vogt-Koyanagi-Harada syndrome and experimental autoimmune uveitis. Invest Ophthalmol Vis Sci 2010, 51:3567-3574.
• [36]Brereton CF, Sutton CE, Lalor SJ, Lavelle EC, Mills KHG: Inhibition of ERK MAPK suppresses IL-23 and IL-1-driven IL-17 production and attenuates autoimmune disease. J Immunol 2009, 183:1715-1723.
• [37]Hammaker D, Firestein GS: 'Go upstream, young man': lessons learnt from the p38 saga. Ann Rheum Dis 2010, 69(Suppl.1):77-82.
• [38]Hammaker DR, Boyle DL, Inoue T, Firestein GS: Regulation of the JNK pathway by TGF-beta activated kinase 1 in rheumatoid arthritis synoviocytes. Arthritis Res Ther 2007, 9:R57. BioMed Central Full Text
• [39]Yoshizawa T, Hammaker D, Boyle DL, Corr M, Flavell R, Davis R, Schett G, Firestein GS: Role of MAPK kinase 6 in arthritis: distinct mechanism of action in inflammation and cytokine expression. J Immunol 2009, 183:1360-1367.
• [40]Gaestel M, Mengel A, Bothe U, Asadullah K: Protein kinases as small molecule inhibitor targets in inflammation. Curr Med Chem 2007, 14:2214-2234.
• [41]Kremer JM, Bloom BJ, Breedveld FC, Coombs JH, Fletcher MP, Gruben D, Krishnaswami S, Burgos-Vargas R, Wilkinson B, Zerbini CA, Zwillich SH: The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum 2009, 60:1895-1905.
• [42]Genovese MC, Kavanaugh A, Weinblatt ME, Peterfy C, DiCarlo J, White ML, O'Brien M, Grossbard EB, Magilavy DB: An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents. Arthritis Rheum 2011, 63:337-345.
• [43]Kötter I, Wacker A, Koch S, Henes J, Richter C, Engel A, Günaydin I, Kanz L: Anakinra in patients with treatment-resistant adult-onset Still's disease: four case reports with serial cytokine measurements and a review of the literature. Semin Arthritis Rheum 2007, 37:189-197.
• [44]Braddock M, Quinn A: Targeting IL-1 in inflammatory disease: new opportunities for therapeutic intervention. Nat Rev Drug Discov 2004, 3:330-339.